Eek Emma, van Driel Mieke, Falk Magnus, Hollingworth Samantha A, Merlo Gregory
Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Primary Care Clinical Unit, School of Clinical Medicine, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Pharmacoepidemiol Drug Saf. 2021 Apr;30(4):409-417. doi: 10.1002/pds.5158. Epub 2020 Nov 9.
To compare the dispensed use of antidepressants in Australia and Sweden.
We analysed publicly available data from Australia and Sweden on dispensed use of antidepressants from 2006 to 2018.
The dispensed use of antidepressants has increased in both Australia and Sweden. Australia had a more rapid increase resulting in a higher total use. The utilisation profile was similar in both countries; SSRIs were the most commonly used group, "other antidepressants" were the group that increased the most, and seven of the eight most used substances were the same. There were differences in which antidepressants were most used, with the three most prescribed antidepressants being escitalopram, sertraline, and venlafaxine in Australia; and mirtazapine, sertraline, and citalopram in Sweden.
Dispensed use of antidepressants has increased remarkably in both Australia and Sweden between 2006 and 2018. Although similar with regard to economic status and health care system, use of antidepressants differs between both countries. This may be a result of a combination of factors related to medical, contextual and policy evidence. The differences displayed in this study may reflect varying accessibility of treatments, national programmes enhancing mental health literacy in the population, clinical prescribing guidelines and timing of approval of new antidepressants.
比较澳大利亚和瑞典抗抑郁药的配药使用情况。
我们分析了澳大利亚和瑞典2006年至2018年抗抑郁药配药使用的公开数据。
澳大利亚和瑞典的抗抑郁药配药使用量均有所增加。澳大利亚增长更快，导致总使用量更高。两国的使用情况相似；选择性5-羟色胺再摄取抑制剂（SSRIs）是最常用的类别，“其他抗抑郁药”是增长最多的类别，且最常用的八种药物中有七种相同。两国最常用的抗抑郁药存在差异，澳大利亚处方量最高的三种抗抑郁药是艾司西酞普兰、舍曲林和文拉法辛；瑞典则是米氮平、舍曲林和西酞普兰。
2006年至2018年期间，澳大利亚和瑞典的抗抑郁药配药使用量均显著增加。尽管两国在经济状况和医疗保健系统方面相似，但抗抑郁药的使用情况存在差异。这可能是与医学、背景和政策证据相关的多种因素共同作用的结果。本研究中显示的差异可能反映了治疗的可及性、提高公众心理健康素养的国家计划、临床处方指南以及新抗抑郁药的获批时间的不同。
